APA

Andritsos L. A., Grieselhuber N. R., Anghelina M., Rogers K. A., Roychowdhury S., Reeser J. W., Timmers C. D., Freud A. G., Blachly J. S., Lucas D. M., Lozanski G., Jones J. A., Williams K., Oakes C., Jones D. & Grever M. R. (20190125). Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. : Leukemia & lymphoma.

Chicago

Andritsos Leslie A, Grieselhuber Nicole R, Anghelina Mirela, Rogers Kerry A, Roychowdhury Sameek, Reeser Julie W, Timmers Cynthia D, Freud Aharon G, Blachly James S, Lucas David M, Lozanski Gerard, Jones Jeffrey A, Williams Katie, Oakes Christopher, Jones Dan and Grever Michael R. 20190125. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. : Leukemia & lymphoma.

Harvard

Andritsos L. A., Grieselhuber N. R., Anghelina M., Rogers K. A., Roychowdhury S., Reeser J. W., Timmers C. D., Freud A. G., Blachly J. S., Lucas D. M., Lozanski G., Jones J. A., Williams K., Oakes C., Jones D. and Grever M. R. (20190125). Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. : Leukemia & lymphoma.

MLA

Andritsos Leslie A, Grieselhuber Nicole R, Anghelina Mirela, Rogers Kerry A, Roychowdhury Sameek, Reeser Julie W, Timmers Cynthia D, Freud Aharon G, Blachly James S, Lucas David M, Lozanski Gerard, Jones Jeffrey A, Williams Katie, Oakes Christopher, Jones Dan and Grever Michael R. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. : Leukemia & lymphoma. 20190125.